Diabetes in Women of Childbearing Age





T Kader, MD, FRCPC





# **DIABETES CANADA**

2018 Clinical Practice Guidelines

#### **Diabetes and Pregnancy**

**Chapter 36** 

Denice S Feig MD FRCPC, Howard Berger MD, Lois Donovan MD FRCPC, Ariane Godbout MD FRCPC, Tina Kader MD FRCPC, Erin Keely MD FRCPC, Rema Sanghera MA RD

#### conflict of interests

- merck
- sanofi
- novonordisk
- eli lilly
- bms
- astrazeneca
- jansenn



#### disclosures

 No disclosures for this presentation



### ROLE OF FAMILY MD IN DIABETIC WOMEN OF CHILDBEARING YEARS

- A) MINIMAL ROLE
- B) IMPORTANT ROLE
- · C) NO ROLE



### COUNSELING FOR DIABETIC WOMEN OF CHILDBEARING YEARS

- A) I DON'T DISCUSS THIS TOPIC
- B) I BRING IT UP EACH VISIT
- C) I ONLY DISCUSS IF PATIENTS ASK



### OPTIMAL A1C FOR WOMEN TRYING TO GET PREGNANT

- 1) 0.06 AND LESS
- 2) 0.065 AND LESS
- 3) 0.07 BUT AIM FOR 0.065 IF CAN BE DONE SAFELY
- 4) .075



### WHAT MEDS ARE SAFE TO GET PREGNANT WITH

- A) METFORMIN
- B) DIABETA
- C) METFORMIN AND DIABETA
- D) DPP4
- E) SGLT2 INHIBITOR
- F) GLP1 AGONIST



### WHAT DO YOU TELL WOMEN ON ACE; ARB AND STATIN WHO WANT TO GET PREGNANT

- A) CONTINUE UNTIL PREGNANT
- B) STOP BEFORE PREGNANCY
- C) NOT SURE



#### Diabetes in Pregnancy: 2 Categories

Pregestational diabetes	Gestational diabetes
Pregnancy in pre-existing diabetes  • Type 1 diabetes  • Type 2 diabetes	Diabetes diagnosed in pregnancy



#### Diabetes in Pregnancy: Consider Phases

Pregestational diabetes	Gestational diabetes
1. Preconception counseling	1. Prevention, Screening & Diagnosis
2. Management during pregnancy	2. Management during Pregnancy
3. Management in labour	3. Management in labour
4. Postpartum considerations	4. Postpartum considerations



#### Diabetes in Pregnancy: Consider Phases

Pregestational diabetes	Gestational diabetes
1. Preconception counseling	1. Prevention, Screening & Diagnosis
2. Management during pregnancy	2. Management during Pregnancy
3. Management in labour	3. Management in labour
4. Postpartum considerations	4. Postpartum considerations






#### Case

- 30 year old patient
- Wants to get pregnant
- Type 2 diabetes for 10 years
- on Komboglyze 2.5;1000 bid
- Complications; mild retinopathy
- Microalbumin positive

A1C 8.0%

What do you advise as her family physician?

# Risk of Fetal Anomaly Relative to Periconceptional A1C





#### **Recommendation 1**

#### **Pre-existing Diabetes**

#### Preconception care

1. All women of reproductive age with type 1 or type 2 diabetes should receive ongoing counselling on reliable birth control, the importance of glycemic control prior to pregnancy, the impact of BMI on pregnancy outcomes, the need for folic acid and the need to stop potentially embryopathic drugs prior to pregnancy [Grade D, Level 4]



#### **Recommendation 2**

**Pre-existing Diabetes** 

#### Preconception care

2. Women with type 2 diabetes with **irregular menses/PCOS** who **lose significant weight** or are started on **metformin** or a **TZD** should be advised that **fertility may improve** and be counselled regarding possible pregnancy and receive preconception counseling [Grade D, Consensus]



#### Screen for Complications: Pre-pregnancy and Intrapartum

Screening for:

- 1.Retinopathy: Need ophthalmological evaluation
- **2.Nephropathy**: Assess creatinine + urine albumin to creatinine ratio (ACR)
  - Women with albuminuria or overt nephropathy are at
     † risk for hypertension and preeclampsia



# Preconception Checklist for Women with Pre-existing Diabetes



- ✓ Use **reliable birth control** until adequate glycemic control
- ✓ Attain a **preconception A1C of \leq7.0%** ( $\leq$  6.5% if safe)
- ✓ May remain on **metformin** + **glyburide** until pregnancy, otherwise **switch** to insulin
- ✓ Assess for and manage any **diabetes complications**
- ✓ Folic Acid 1 mg/d: 3 months pre-conception to 12 weeks post-conception
- ✓ **Discontinue** potential embryopathic meds:
  - ✓ **ACE inhibitors / ARB** (prior to or upon detection of pregnancy in those with significant proteinuria)
  - ✓ **Statin** therapy



### **She is Now Pregnant!!**

- She sees her endocrinologist
- Transferred to basal bolus insulin regimen
- Lantus 30 units SC qhs
- Novorapid 12 units SC ac meals
- Metformin 500 TID
- Is metformin safe?
- What do you recommend for fetal surveillance?





#### **Recommendation 4**

#### **Pre-existing Diabetes**

#### Preconception care

4. Women on **metformin** and/or **glyburide** preconception **may continue** on these agents if glycemic control is adequate until pregnancy is achieved [Grade C, Level 3]. Women on other antihyperglycemic agents, should **switch to insulin prior to conception** as there are no safety data for the use of other antihyperglycemic agents in pregnancy [Grade D, Consensus]





#### **Recommendation 13**

#### **Pre-existing Diabetes**

#### Management in pregnancy

13. Women with pre-existing diabetes should **start ASA 81 mg daily at 12-16 weeks gestation** to reduce the risk of preeclampsia [Grade D, Level 4]



# **Pregnancy Management for Pre-existing Diabetes**

#### Retinopathy Surveillance

- one visit in first trimester
- visits thereafter: as needed
- more often in:
  - more severe retinopathy
  - large drop in A1C
  - poor glycemic control

#### Nephropathy

- Good BP control
- Watch for hypertension, preeclampsia



# **Pregnancy Management for Pre-existing Diabetes**

- Type 1 diabetes: **Continuous glucose monitoring** should be considered in all women
- Encourage weight gain according to Institute of Medicine recommendations
- ASA to reduce the risk of pre-eclampsia, starting at 12-16 weeks gestational age

LGA, large for gestational age; NICU, neonatal intensive care unit; ASA, acetylsalicylic acid



#### **Diabetes in Pregnancy: Consider Phases**

Pregestational diabetes	Gestational diabetes
1. Preconception counseling	1. Prevention, Screening & Diagnosis
2. Management during pregnancy	2. Management during Pregnancy
3. Management in labour	3. Management in labour
4. Postpartum considerations	4. Postpartum considerations



## **Pregnancy Management for Pre-existing Diabetes**

Perform SMBG pre- and postprandially

Target BG values		
Fasting and pre-prandial BG <5.3 mmol/L		
1h postprandial BG <7.8 mmol/L		
2h postprandial BG <6.7 mmol/L		

- Aim for A1C  $\leq 6.5\%$  ( $\leq 6.1\%$  if possible)
  - Lower late stillbirth & infant death
- Individualize targets in those with severe hypoglycemia/unawareness



# Pregnancy Management for Pre-existing Diabetes: Fetal Surveillance & Delivery

- Fetal surveillance should be started at 30-32 wks gestational age, then weekly from 34-36 wks until delivery
- Earlier onset and/or more frequent: those at highest risk
- Uncomplicated: induce 38-39 wks gestational age to decrease stillbirth
- Induction prior to 38 wks for other fetal/maternal indications





#### **Recommendation 16**

#### **Pre-existing Diabetes**

#### Fetal surveillance and timing of delivery

16. In women with pre-existing diabetes, assessment of fetal well-being should be performed at 30-32 weeks gestation and performed weekly starting at 34-36 weeks gestation and continued until delivery [Grade D, Consensus]. Earlier onset and/or more frequent fetal health surveillance is recommended in those considered at highest risk [Grade D, Consensus]




#### MiTy Trial



# Metformin in Women with Type 2 Diabetes in Pregnancy Trial

CIHR funded study June 2010





#### Aim of the Study

Secondary Research Questions:

#### Maternal outcomes:

- -maternal weight gain,
- -maternal insulin doses
- -maternal glycemic control as measured by HbA1c and capillary glucose measures, rates of maternal hypoglycemia
- -pre-eclampsia and/or gestational hypertension
- -rate of cesarean delivery
- -number of hospitalizations prior to admission for delivery
- -the duration of hospital stay for the mother



#### Maternal Outcomes

	Metformin	Placebo
	N=240	N=242
Maternal weight gain (kg)*		
Overall weight gain	7·2±5·3	9·0±4·7
Weekly weight gain	0·4±0·3	0·5±0·3
Last HbA1c in pregnancy <sup>‡</sup>		
% (mean±SD)	5·90%±0·78	6·10%±0·94
mmol/mol (mean±SD) ————	41·0±8·5	43·2±-10
*Overall and weekly weight gain was calculated from	m measured weight at randomisation.	MiTy
*Overall and weekly weight gain was calculated from # After adjusting for baseline HbA1c at randomisation.  Mean glucose mmol/l	6.05 [0.93]	6.27 [0.9
, , , , , ,		

#### Maternal Outcomes

	Metformin	Placebo
	N=240	N=242
Total insulin dose (units/kg/day) a <del>t 34 or 36 weeks</del> (mean±SD)§	- 1·1±1·0	1·5±1·1
Total insulin dose (units/day) at 34 or 36 weeks (mean±SD)	109·8±105·1	155·3±13
Long-acting (units/day) at 34 or 36 weeks (mean±SD)	42·8±46·0	55·7±47·6
Short-acting (units/day) at 34 or 36 weeks (mean±SD)**	66·9±75·1	99·1±108

#### Neonatal Outcomes



#### **Neonatal Outcomes**

	Metformin	Placebo	P-Value	Effect size
Live births	N=232	N=229		
Large for gestational age >90 <sup>th</sup> centile (adjudicated using Kramer)	50 (21·6%)	66 (28·8%)	0.07	RR 0·74 (0·54, 1·0
Extreme large for gestational age > 97th centile (using Kramer)	20 <del> (8·6%)</del>	34 (14-8%)	0.041	RR 0·58 (0·34, 0·
Birthweight ≥4000g	28 (12·1%)	44 (19·2%)	0.046	RR 0·65 (0·43, 0·
Small for gestational age < 10th centile (using Kramer <sup>25</sup> )	30 (12·9%)	15/228 (6·6%)	0.03	RR 1·96 (1·10, 3·0



## Neonatal Outcomes

	Metformin	Placebo	P-Value	Effect size
Live births	N=232	N=229		
Preterm birth <37 weeks	60 (25·9%)	47 (20·5%)	0.16	RR 1·27 (0·91, 1·77)
Birth injury	1/231 (0·4%)	3/228 (1·3%)	0.37	RR 0·36 (0·04, 3·36)
Respiratory distress	11/231 (4·8%)	8/228 (3·5%)	0.49	RR 1·36 (0·56, 3·29)
Neonatal hypoglycemia	27/231 (11·7%)	34/228 (14.9%)	0.41	RR 0·82 (0·52, 1·30)
High level neonatal care >24 h¶	51/231 (22·1%)	46/228 (20·2%)	0.56	RR 1·10 (0·79, 1·53)



### In Summary

We found several maternal and neonatal benefits in women using metformin:

- Reduced maternal weight gain
- Reduced insulin dose
- Improved glycemic control
- Reduced birthweight (218g), Extreme LGA, >4,000g
- Lower adiposity measures: Reduced skinfolds, abdominal circumferences fat mass

## **Unanswered Questions**

- What are the predictors of SGA in our women?
- Are these SGA babies healthy or unhealthy?
- What is the impact of metformin in offspring of women with T2DM in the long-term?
  - Will there be a benefit due to



## Diabetes in Pregnancy: Consider Phases

Pregestational diabetes	Gestational diabetes
1. Preconception counseling	1. Prevention, Screening & Diagnosis
2. Management during pregnancy	2. Management during Pregnancy
3. Management in labour	3. Management in labour
4. Postpartum considerations	4. Postpartum considerations



# Pregnancy Management for Pre-existing Diabetes: Intrapartum Glucose Management

- Monitor closely. Keep blood glucose 4.0-7.0 mmol/L to reduce neonatal hypoglycemia
- CSII can be continued in women who choose to stay on their pump, and they or their partner can independently manage the pump





### Postpartum care for pre-existing diabetes

- 1. Adjust insulin → at risk of hypoglycemia
- 2. Encourage women to breastfeed:
  - Reduce neonatal hypoglycemia, offspring obesity
- 3. Metformin and glyburide may be used during breast-feeding → no long term data but appears safe
- 4. Screen for postpartum thyroiditis in type 1 diabetes → check TSH at 2-4 months postpartum



### **Diabetes in Pregnancy: Consider Phases**

Pregestational diabetes	Gestational diabetes
1. Preconception counseling	1. Prevention, Screening & Diagnosis
2. Management during pregnancy	2. Management during Pregnancy
3. Management in labour	3. Management in labour
4. Postpartum considerations	4. Postpartum considerations



### CASE OF GDM

- 24 year old girl
- born in india
- both parents; type 2 diabetes
- 26 weeks pregnant
- glucose screen 50 gram
- 14.2
- a1c o.o62
- started on insulin during pregnancy
- could she use meds



# **Early Screening for Women at High Risk for Type 2 Diabetes**

Women at high risk of type 2 diabetes



Screen with A1C (or FPG if A1C unreliable) in first trimester



A1C ≥6.5% or FPG ≥7.0 mmol/L → treat like type 2 diabetes



Confirm diagnosis post-partum



### Why Diagnose and Treat GDM?

- Macrosomia
- Shoulder dystocia and nerve injury
- Neonatal hypoglycemia
- Preterm delivery
- Hyperbilirubinemia

- Caesarian section
- Offspring obesity
- Offspring diabetes



# Gestational Diabetes (GDM) Screening


Universal screening for GDM


@ 24-28 weeks gestational age

Screen earlier if risk factors for GDM (see next slide)



### **2018 GDM Diagnosis: Two Approaches**







### **Recommendation 28**

### **Gestational Diabetes**

### **Diagnosis**

- 28. An **alternative approach** to screen and diagnose GDM is the **1-step approach**: a **75 g OGTT** should be performed (with no prior screening 50 g GCT) as the diagnostic test for GDM using the 1 of the following criteria:
  - Fasting PG >5.1 mmol/L OR
  - 1 hour PG >10.0 mmol/L OR
  - 2 hours PG >8.5 mmol/L [Grade B, Level 1]



### Diabetes in Pregnancy: Consider Phases

Pregestational diabetes	Gestational diabetes
1. Preconception counseling	1. Prevention, Screening & Diagnosis
2. Management during pregnancy	2. Management during Pregnancy
3. Management in labour	3. Management in labour
4. Postpartum considerations	4. Postpartum considerations



### **GDM: Management During Pregnancy**

- Receive nutrition counseling by registered dietician to achieve their nutrition, weight and blood glucose goals
- Eat healthy diet and Replace high-Glycemic Index foods with low-Glycemic Index foods to reduce need for insulin initiation and decrease birthweight
- Discuss appropriate weight gain and healthy lifestyle interventions throughout pregnancy
- Recommend weight gain according to IOM recommendations based on prepregnancy BMI interventions to reduce LGA, C-section



# Institute of Medicine Guidelines for Gestational Weight Gain

Pre-Pregnancy BMI (kg/m²)	Recommended range of total weight gain (kg)	Recommended range of total weight gain (lb)
BMI <18.5	12.5 - 18.0	28 - 40
BMI 18.5 – 24.9	11.5 - 16.0	25 – 35
BMI 25.0 – 29.9	7.0 - 11.5	15 - 23
BMI <u>&gt;</u> 30	5.0 - 9.0	11 - 20

Recommended rate of weight gain and total weight gain for singleton Pregnancies according to pre-pregnancy BMI



### **GDM:** Management During Pregnancy

- Perform SMBG fasting and postprandially
- Glycemic targets during pregnancy:

# Target BG values Fasting and preprandial BG <5.3 mmol/L 1h postprandial BG <7.8 mmol/L 2h postprandial BG <6.7 mmol/L

• If glycemic targets not achieved within 1-2 weeks, initiate pharmacologic therapy



### **GDM: Management During Pregnancy**

- Insulin first-line
  - May use aspart, lispro, glulisine: perinatal outcomes similar
- Metformin may be used as an alternative to insulin
  - Good safety data in pregnancy
  - Evidence of less maternal weight gain, less large-for-gestationalage, less neonatal hypoglycemia
  - Women should be informed that it crosses the placenta
  - Safety data in offspring postpartum up to 2 years
  - Insulin necessary in 40% on metformin
- Glyburide may be used in women who refuse insulin and not well controlled on metformin



## MiG Trial - Design

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

### Metformin versus Insulin for the Treatment of Gestational Diabetes

Janet A. Rowan, M.B., Ch.B., William M. Hague, M.D., Wanzhen Gao, Ph.D., Malcolm R. Battin, M.B., Ch.B., and M. Peter Moore, M.B., Ch.B., for the MiG Trial Investigators\*

- RCT 750 women with GDM
- Randomized to Metformin vs Insulin
- Primary Outcome: Composite of neonatal outcomes included hypoglycemia, respiratory distress, phototherapy, birth trauma, low 5 min APGAR, and



### DIABETA

- studies show can be used for gdm (2000 Langhers)
- 80 percent as effective as insulin
- but recently adverse neonatal outcomes such as hypoglycemia; has limited its use to third line after insulin and metformin





### **Recommendation 34**

### **Gestational Diabetes**

Management during pregnancy

34. In women with GDM who decline insulin and do not tolerate or are inadequately controlled on metformin, glyburide may be used [Grade B, Level 2]





### **Recommendation 36**

### **Gestational Diabetes**

### Fetal surveillance and timing of delivery in GDM

36. Women with GDM can be offered **induction** of labour between **38-40 weeks** gestation to potentially reduce the risk of stillbirth [Grade D, Consensus] and the risk of caesarean section [Grade C, Level 2]. Earlier or later induction of labour should be considered based on glycemic control and the presence or absence of other comorbid conditions [Grade D, Consensus]



# GDM: Glycemic Management During Labour and Delivery

• Keep maternal blood glucose between 4.0 and 7.0 mmol/L → reduce risk of neonatal hypoglycemia




## Diabetes in Pregnancy: Consider Phases

Pregestational diabetes	Gestational diabetes
1. Preconception counseling	1. Prevention, Screening & Diagnosis
2. Management during pregnancy	2. Management during Pregnancy
3. Management in labour	3. Management in labour
4. Postpartum considerations	4. Postpartum considerations



# GDM: Postpartum OGTT





### **Breast feeding**


- mothers that nurse
- lower body weight
- improved insulin secretion
- less diabetes at 10 years
- longer duration and more intense should be encouraged
- mothers with gdm may initiate nursing but have harder time continuing





### **IGT AFTER GDM**

- DPP STUDIES A GDM GROUP
- LIFESTYLE AND METFORMIN CAN DECREASE TYPE 2 DM IN GDM WITH IGT
- SHOULD BE OFFERERED TO PATIENTS
- RESULTS ARE IMPRESSIVE







ere."

# Diabetes Canada Clinical Practice Guidelines

<u>www.guidelines.diabetes.ca</u> – for health-care providers

1-800-BANTING (226-8464)

www.diabetes.ca - for people with diabetes

